GlaxoSmithKline’s bid for Human Genome Sciences cleared, but rejected by HGS Board
The Hart-Scott-Rodino waiting period for GlaxoSmithKline’s (GSK) tender offer for Human Genome Sciences (HGS) has expired. Human Genome Sciences is a Rockville, MD-based biopharmaceutical corporation. Under the terms of the offer, GSK would buy all outstanding shares of HGS for $13/share in cash.
However, the HGS Board of Directors has rejected the offer as inadequate and urged shareholders to reject the offer as well. According to the HGS press release in response to the HSR termination announcement, GSK’s tender offer was unsolicited and “seeks to circumvent, disrupt and prematurely end [HGS’s] strategic review process.
Full content: MarketWatch
Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Agri Stats Must Face Price-Fixing Lawsuit, Judge Rules
May 29, 2024 by
CPI
States Ramp Up Antitrust Efforts with Expanding Legal Teams
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI